Industry Research Reports

Home > Reports > Pharma & Healthcare > Global Omalizumab Biosimilars Market Research Report 2025

Global Omalizumab Biosimilars Market Research Report 2025

Industry: Pharma & Healthcare

Published Date: 2025-01-16

Pages: 90 Pages

Report ld: 3456253

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Omalizumab Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omalizumab Biosimilars.

The Omalizumab Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Omalizumab Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Omalizumab Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

Roche

Novartis

Glenmark Pharmaceuticals

Selexis

Generium

CuraTeQ

Celltrion Healthcare

Alvotech

BiosanaPharma

Mabpharm

CSPC Pharmaceutical Group

Biomabs

HisunPharm

Segment by Type

150 mg/mL

75 mg/0.5 mL

Segment by Application

Persistent Asthma

Nasal Polyps

Chronic Idiopathic Urticaria

Consumption by Region

North America

U.S.

Canada

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Europe

Germany

France

U.K.

Italy

Russia

Latin America

Mexico

Brazil

Argentina

Middle East and Africa

Turkey

Saudi Arabia

U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Omalizumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Omalizumab Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Omalizumab Biosimilars Market Overview

1.1 Product Definition

1.2 Omalizumab Biosimilars by Type

1.2.1 Global Omalizumab Biosimilars Market Value Comparison by Type (2024 VS 2031)

1.2.2 150 mg/mL

1.2.3 75 mg/0.5 mL

1.3 Omalizumab Biosimilars by Application

1.3.1 Global Omalizumab Biosimilars Market Value by Application (2024 VS 2031)

1.3.2 Persistent Asthma

1.3.3 Nasal Polyps

1.3.4 Chronic Idiopathic Urticaria

1.4 Global Omalizumab Biosimilars Market Size Estimates and Forecasts

1.4.1 Global Omalizumab Biosimilars Revenue 2020-2031

1.4.2 Global Omalizumab Biosimilars Sales 2020-2031

1.4.3 Global Omalizumab Biosimilars Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Omalizumab Biosimilars Market Competition by Manufacturers

2.1 Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

2.2 Global Omalizumab Biosimilars Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Omalizumab Biosimilars Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application

2.7 Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry

2.8 Global Omalizumab Biosimilars Market Competitive Situation and Trends

2.8.1 Global Omalizumab Biosimilars Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Omalizumab Biosimilars Players Market Share by Revenue

2.8.3 Global Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Omalizumab Biosimilars Market Scenario by Region

3.1 Global Omalizumab Biosimilars Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Omalizumab Biosimilars Sales by Region: 2020-2031

3.2.1 Global Omalizumab Biosimilars Sales by Region: 2020-2025

3.2.2 Global Omalizumab Biosimilars Sales by Region: 2026-2031

3.3 Global Omalizumab Biosimilars Revenue by Region: 2020-2031

3.3.1 Global Omalizumab Biosimilars Revenue by Region: 2020-2025

3.3.2 Global Omalizumab Biosimilars Revenue by Region: 2026-2031

3.4 North America Omalizumab Biosimilars Market Facts & Figures by Country

3.4.1 North America Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Omalizumab Biosimilars Sales by Country (2020-2031)

3.4.3 North America Omalizumab Biosimilars Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Omalizumab Biosimilars Market Facts & Figures by Country

3.5.1 Europe Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Omalizumab Biosimilars Sales by Country (2020-2031)

3.5.3 Europe Omalizumab Biosimilars Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Omalizumab Biosimilars Market Facts & Figures by Region

3.6.1 Asia Pacific Omalizumab Biosimilars Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Omalizumab Biosimilars Sales by Region (2020-2031)

3.6.3 Asia Pacific Omalizumab Biosimilars Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Omalizumab Biosimilars Market Facts & Figures by Country

3.7.1 Latin America Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Omalizumab Biosimilars Sales by Country (2020-2031)

3.7.3 Latin America Omalizumab Biosimilars Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Omalizumab Biosimilars Market Facts & Figures by Country

3.8.1 Middle East and Africa Omalizumab Biosimilars Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Omalizumab Biosimilars Sales by Country (2020-2031)

3.8.3 Middle East and Africa Omalizumab Biosimilars Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Omalizumab Biosimilars Sales by Type (2020-2031)

4.1.1 Global Omalizumab Biosimilars Sales by Type (2020-2025)

4.1.2 Global Omalizumab Biosimilars Sales by Type (2026-2031)

4.1.3 Global Omalizumab Biosimilars Sales Market Share by Type (2020-2031)

4.2 Global Omalizumab Biosimilars Revenue by Type (2020-2031)

4.2.1 Global Omalizumab Biosimilars Revenue by Type (2020-2025)

4.2.2 Global Omalizumab Biosimilars Revenue by Type (2026-2031)

4.2.3 Global Omalizumab Biosimilars Revenue Market Share by Type (2020-2031)

4.3 Global Omalizumab Biosimilars Price by Type (2020-2031)

5 Segment by Application

5.1 Global Omalizumab Biosimilars Sales by Application (2020-2031)

5.1.1 Global Omalizumab Biosimilars Sales by Application (2020-2025)

5.1.2 Global Omalizumab Biosimilars Sales by Application (2026-2031)

5.1.3 Global Omalizumab Biosimilars Sales Market Share by Application (2020-2031)

5.2 Global Omalizumab Biosimilars Revenue by Application (2020-2031)

5.2.1 Global Omalizumab Biosimilars Revenue by Application (2020-2025)

5.2.2 Global Omalizumab Biosimilars Revenue by Application (2026-2031)

5.2.3 Global Omalizumab Biosimilars Revenue Market Share by Application (2020-2031)

5.3 Global Omalizumab Biosimilars Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Omalizumab Biosimilars Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Omalizumab Biosimilars Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Glenmark Pharmaceuticals

6.3.1 Glenmark Pharmaceuticals Company Information

6.3.2 Glenmark Pharmaceuticals Description and Business Overview

6.3.3 Glenmark Pharmaceuticals Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Glenmark Pharmaceuticals Omalizumab Biosimilars Product Portfolio

6.3.5 Glenmark Pharmaceuticals Recent Developments/Updates

6.4 Selexis

6.4.1 Selexis Company Information

6.4.2 Selexis Description and Business Overview

6.4.3 Selexis Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Selexis Omalizumab Biosimilars Product Portfolio

6.4.5 Selexis Recent Developments/Updates

6.5 Generium

6.5.1 Generium Company Information

6.5.2 Generium Description and Business Overview

6.5.3 Generium Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Generium Omalizumab Biosimilars Product Portfolio

6.5.5 Generium Recent Developments/Updates

6.6 CuraTeQ

6.6.1 CuraTeQ Company Information

6.6.2 CuraTeQ Description and Business Overview

6.6.3 CuraTeQ Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.6.4 CuraTeQ Omalizumab Biosimilars Product Portfolio

6.6.5 CuraTeQ Recent Developments/Updates

6.7 Celltrion Healthcare

6.7.1 Celltrion Healthcare Company Information

6.7.2 Celltrion Healthcare Description and Business Overview

6.7.3 Celltrion Healthcare Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Celltrion Healthcare Omalizumab Biosimilars Product Portfolio

6.7.5 Celltrion Healthcare Recent Developments/Updates

6.8 Alvotech

6.8.1 Alvotech Company Information

6.8.2 Alvotech Description and Business Overview

6.8.3 Alvotech Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Alvotech Omalizumab Biosimilars Product Portfolio

6.8.5 Alvotech Recent Developments/Updates

6.9 BiosanaPharma

6.9.1 BiosanaPharma Company Information

6.9.2 BiosanaPharma Description and Business Overview

6.9.3 BiosanaPharma Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.9.4 BiosanaPharma Omalizumab Biosimilars Product Portfolio

6.9.5 BiosanaPharma Recent Developments/Updates

6.10 Mabpharm

6.10.1 Mabpharm Company Information

6.10.2 Mabpharm Description and Business Overview

6.10.3 Mabpharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Mabpharm Omalizumab Biosimilars Product Portfolio

6.10.5 Mabpharm Recent Developments/Updates

6.11 CSPC Pharmaceutical Group

6.11.1 CSPC Pharmaceutical Group Company Information

6.11.2 CSPC Pharmaceutical Group Description and Business Overview

6.11.3 CSPC Pharmaceutical Group Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.11.4 CSPC Pharmaceutical Group Omalizumab Biosimilars Product Portfolio

6.11.5 CSPC Pharmaceutical Group Recent Developments/Updates

6.12 Biomabs

6.12.1 Biomabs Company Information

6.12.2 Biomabs Description and Business Overview

6.12.3 Biomabs Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Biomabs Omalizumab Biosimilars Product Portfolio

6.12.5 Biomabs Recent Developments/Updates

6.13 HisunPharm

6.13.1 HisunPharm Company Information

6.13.2 HisunPharm Description and Business Overview

6.13.3 HisunPharm Omalizumab Biosimilars Sales, Revenue and Gross Margin (2020-2025)

6.13.4 HisunPharm Omalizumab Biosimilars Product Portfolio

6.13.5 HisunPharm Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Omalizumab Biosimilars Industry Chain Analysis

7.2 Omalizumab Biosimilars Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Omalizumab Biosimilars Production Mode & Process Analysis

7.4 Omalizumab Biosimilars Sales and Marketing

7.4.1 Omalizumab Biosimilars Sales Channels

7.4.2 Omalizumab Biosimilars Distributors

7.5 Omalizumab Biosimilars Customer Analysis

8 Omalizumab Biosimilars Market Dynamics

8.1 Omalizumab Biosimilars Industry Trends

8.2 Omalizumab Biosimilars Market Drivers

8.3 Omalizumab Biosimilars Market Challenges

8.4 Omalizumab Biosimilars Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Global Omalizumab Biosimilars Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Omalizumab Biosimilars Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Omalizumab Biosimilars Market Competitive Situation by Manufacturers in 2024

Table 4. Global Omalizumab Biosimilars Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Omalizumab Biosimilars Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Omalizumab Biosimilars Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Omalizumab Biosimilars Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Omalizumab Biosimilars Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Omalizumab Biosimilars, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Omalizumab Biosimilars, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Omalizumab Biosimilars, Product Type & Application

Table 12. Global Key Manufacturers of Omalizumab Biosimilars, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Omalizumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Omalizumab Biosimilars as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Omalizumab Biosimilars Sales by Region (2020-2025) & (K Units)

Table 18. Global Omalizumab Biosimilars Sales Market Share by Region (2020-2025)

Table 19. Global Omalizumab Biosimilars Sales by Region (2026-2031) & (K Units)

Table 20. Global Omalizumab Biosimilars Sales Market Share by Region (2026-2031)

Table 21. Global Omalizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Omalizumab Biosimilars Revenue Market Share by Region (2020-2025)

Table 23. Global Omalizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Omalizumab Biosimilars Revenue Market Share by Region (2026-2031)

Table 25. North America Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)

Table 27. North America Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)

Table 28. North America Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)

Table 32. Europe Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)

Table 33. Europe Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Omalizumab Biosimilars Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Omalizumab Biosimilars Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Omalizumab Biosimilars Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Omalizumab Biosimilars Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Omalizumab Biosimilars Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Omalizumab Biosimilars Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Omalizumab Biosimilars Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Omalizumab Biosimilars Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Omalizumab Biosimilars Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Omalizumab Biosimilars Sales (K Units) by Type (2020-2025)

Table 51. Global Omalizumab Biosimilars Sales (K Units) by Type (2026-2031)

Table 52. Global Omalizumab Biosimilars Sales Market Share by Type (2020-2025)

Table 53. Global Omalizumab Biosimilars Sales Market Share by Type (2026-2031)

Table 54. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Omalizumab Biosimilars Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Omalizumab Biosimilars Revenue Market Share by Type (2020-2025)

Table 57. Global Omalizumab Biosimilars Revenue Market Share by Type (2026-2031)

Table 58. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2020-2025)

Table 59. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2026-2031)

Table 60. Global Omalizumab Biosimilars Sales (K Units) by Application (2020-2025)

Table 61. Global Omalizumab Biosimilars Sales (K Units) by Application (2026-2031)

Table 62. Global Omalizumab Biosimilars Sales Market Share by Application (2020-2025)

Table 63. Global Omalizumab Biosimilars Sales Market Share by Application (2026-2031)

Table 64. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Omalizumab Biosimilars Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Omalizumab Biosimilars Revenue Market Share by Application (2020-2025)

Table 67. Global Omalizumab Biosimilars Revenue Market Share by Application (2026-2031)

Table 68. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2020-2025)

Table 69. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2026-2031)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Roche Omalizumab Biosimilars Product

Table 74. Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Novartis Omalizumab Biosimilars Product

Table 79. Novartis Recent Developments/Updates

Table 80. Glenmark Pharmaceuticals Company Information

Table 81. Glenmark Pharmaceuticals Description and Business Overview

Table 82. Glenmark Pharmaceuticals Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Glenmark Pharmaceuticals Omalizumab Biosimilars Product

Table 84. Glenmark Pharmaceuticals Recent Developments/Updates

Table 85. Selexis Company Information

Table 86. Selexis Description and Business Overview

Table 87. Selexis Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Selexis Omalizumab Biosimilars Product

Table 89. Selexis Recent Developments/Updates

Table 90. Generium Company Information

Table 91. Generium Description and Business Overview

Table 92. Generium Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Generium Omalizumab Biosimilars Product

Table 94. Generium Recent Developments/Updates

Table 95. CuraTeQ Company Information

Table 96. CuraTeQ Description and Business Overview

Table 97. CuraTeQ Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. CuraTeQ Omalizumab Biosimilars Product

Table 99. CuraTeQ Recent Developments/Updates

Table 100. Celltrion Healthcare Company Information

Table 101. Celltrion Healthcare Description and Business Overview

Table 102. Celltrion Healthcare Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Celltrion Healthcare Omalizumab Biosimilars Product

Table 104. Celltrion Healthcare Recent Developments/Updates

Table 105. Alvotech Company Information

Table 106. Alvotech Description and Business Overview

Table 107. Alvotech Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Alvotech Omalizumab Biosimilars Product

Table 109. Alvotech Recent Developments/Updates

Table 110. BiosanaPharma Company Information

Table 111. BiosanaPharma Description and Business Overview

Table 112. BiosanaPharma Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. BiosanaPharma Omalizumab Biosimilars Product

Table 114. BiosanaPharma Recent Developments/Updates

Table 115. Mabpharm Company Information

Table 116. Mabpharm Description and Business Overview

Table 117. Mabpharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Mabpharm Omalizumab Biosimilars Product

Table 119. Mabpharm Recent Developments/Updates

Table 120. CSPC Pharmaceutical Group Company Information

Table 121. CSPC Pharmaceutical Group Description and Business Overview

Table 122. CSPC Pharmaceutical Group Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 123. CSPC Pharmaceutical Group Omalizumab Biosimilars Product

Table 124. CSPC Pharmaceutical Group Recent Developments/Updates

Table 125. Biomabs Company Information

Table 126. Biomabs Description and Business Overview

Table 127. Biomabs Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 128. Biomabs Omalizumab Biosimilars Product

Table 129. Biomabs Recent Developments/Updates

Table 130. HisunPharm Company Information

Table 131. HisunPharm Description and Business Overview

Table 132. HisunPharm Omalizumab Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 133. HisunPharm Omalizumab Biosimilars Product

Table 134. HisunPharm Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Omalizumab Biosimilars Distributors List

Table 138. Omalizumab Biosimilars Customers List

Table 139. Omalizumab Biosimilars Market Trends

Table 140. Omalizumab Biosimilars Market Drivers

Table 141. Omalizumab Biosimilars Market Challenges

Table 142. Omalizumab Biosimilars Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Omalizumab Biosimilars

Figure 2. Global Omalizumab Biosimilars Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Omalizumab Biosimilars Market Share by Type: 2024 & 2031

Figure 4. 150 mg/mL Product Picture

Figure 5. 75 mg/0.5 mL Product Picture

Figure 6. Global Omalizumab Biosimilars Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Omalizumab Biosimilars Market Share by Application: 2024 & 2031

Figure 8. Persistent Asthma

Figure 9. Nasal Polyps

Figure 10. Chronic Idiopathic Urticaria

Figure 11. Global Omalizumab Biosimilars Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Omalizumab Biosimilars Market Size (2020-2031) & (US$ Million)

Figure 13. Global Omalizumab Biosimilars Sales (2020-2031) & (K Units)

Figure 14. Global Omalizumab Biosimilars Average Price (USD/Unit) & (2020-2031)

Figure 15. Omalizumab Biosimilars Report Years Considered

Figure 16. Omalizumab Biosimilars Sales Share by Manufacturers in 2024

Figure 17. Global Omalizumab Biosimilars Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Omalizumab Biosimilars Players: Market Share by Revenue in Omalizumab Biosimilars in 2024

Figure 19. Omalizumab Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Omalizumab Biosimilars Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Omalizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 22. North America Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 23. U.S. Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Omalizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 26. Europe Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 27. Germany Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Omalizumab Biosimilars Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Omalizumab Biosimilars Revenue Market Share by Region (2020-2031)

Figure 34. China Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Taiwan Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Philippines Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Latin America Omalizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 45. Latin America Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 46. Mexico Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Brazil Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Argentina Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Middle East and Africa Omalizumab Biosimilars Sales Market Share by Country (2020-2031)

Figure 50. Middle East and Africa Omalizumab Biosimilars Revenue Market Share by Country (2020-2031)

Figure 51. Turkey Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Saudi Arabia Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. U.A.E Omalizumab Biosimilars Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Global Sales Market Share of Omalizumab Biosimilars by Type (2020-2031)

Figure 55. Global Revenue Market Share of Omalizumab Biosimilars by Type (2020-2031)

Figure 56. Global Omalizumab Biosimilars Price (USD/Unit) by Type (2020-2031)

Figure 57. Global Sales Market Share of Omalizumab Biosimilars by Application (2020-2031)

Figure 58. Global Revenue Market Share of Omalizumab Biosimilars by Application (2020-2031)

Figure 59. Global Omalizumab Biosimilars Price (USD/Unit) by Application (2020-2031)

Figure 60. Omalizumab Biosimilars Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Omalizumab Biosimilars market? zhanKai

The top companies in the global Omalizumab Biosimilars market are Roche、Novartis、Glenmark Pharmaceuticals.

Related Reports

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 139
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2026-04-16
Pages: 164
USD 4900.00
(Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published Date: 2026-04-16
Pages: 142
USD 4250.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published Date: 2026-04-16
Pages: 120
USD 2900.00
(Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 119
USD 3950.00
(Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-20
Pages: 90
USD 2900.00
(Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published Date: 2024-01-11
Pages: 122
USD 3950.00
(Single User License)

Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Omalizumab Biosimilars was estimated to be worth US$ 290 million in 2025 and is projected to reach US$ 598 million, growing at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 139
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Omalizumab Biosimilars market is projected to grow from US$ 290 million in 2025 to US$ 598 million by 2032, at a CAGR of 11.2% (2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2026-04-16
Pages: 164
USD 4900.00 (Single User License)
Global Omalizumab Biosimilars Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Omalizumab Biosimilars market size was US$ 290 million in 2025 and is forecast to reach a readjusted size of US$ 598 million by 2032 with a CAGR of 11.2% during the forecast period 2026-2032.
Published: 2026-04-16
Pages: 142
USD 4250.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2026
The global Omalizumab Biosimilars market was valued at US$ 290 million in 2025 and is anticipated to reach US$ 598 million by 2032, at a CAGR of 11.2% from 2026 to 2032.
Published: 2026-04-16
Pages: 120
USD 2900.00 (Single User License)
Omalizumab Biosimilars- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Omalizumab Biosimilars was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 119
USD 3950.00 (Single User License)
Global Omalizumab Biosimilars Market Research Report 2024
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-20
Pages: 90
USD 2900.00 (Single User License)
Omalizumab Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
Published: 2024-01-11
Pages: 122
USD 3950.00 (Single User License)